Abstracts tagged "Juvenile Rheumatoid Arthritis"

Abstract Number: 0366 • ACR Convergence 2023
Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis
Quentin Goossens¹, Miguel Locsin², Emily Moise³, Lori Ponder⁴, Omer Inan¹ and Sampath Prahalad⁵, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Georgia Institute of Technolgy, Atlanta, GA, ⁴Children's Healthcare of Atlanta, Atlanta, GA, ⁵Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a chronic condition in children that causes joint inflammation. Enthesitis-related arthritis (ERA), a subtype of JIA, affects 10-20% of…
Abstract Number: 0870 • ACR Convergence 2022
Knee Acoustic Emissions as a Noninvasive Biomarker of Articular Health in Juvenile Idiopathic Arthritis
Sevda Gharehbaghi¹, Emily Moise¹, Priya Brito², Lori Ponder³, Omer Inan¹ and Sampath Prahalad⁴, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University, Atlanta, GA, ³Children's Healthcare of Atlanta, Atlanta, GA, ⁴Emory + Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile idiopathic arthritis (JIA) refers to all forms of autoimmune arthritis in children with undetermined etiology, and thus it is the most prevalent chronic…
Abstract Number: 1418 • ACR Convergence 2022
Change in Disease Activity and Occurrence of Adverse Events After Initiation of Etanercept in Pediatric Patients with Juvenile Psoriatic Arthritis in the CARRA Registry
Colleen Correll¹, Scott Stryker², David Collier³, Anne Dennos⁴, Stephen Balevic⁵, Thomas Phillips⁵ and Tim Beukelman⁶, ¹University of Minnesota, Minneapolis, MN, ²Amgen Inc., San Francisco, CA, ³Amgen Inc., Simi Valley, CA, ⁴Duke University, Durham, NC, ⁵Duke Clinical Research Institute, Durham, NC, ⁶Childhood Arthritis and Rheumatology Research Alliance (CARRA), Birmingham, AL
Background/Purpose: Juvenile psoriatic arthritis (JPsA) constitutes ~5% of juvenile idiopathic arthritis (JIA). Several therapeutics are available for JPsA; however, given the low JPsA incidence, important…
Abstract Number: 2191 • ACR Convergence 2022
Long-term Outcomes of Children Born to Mothers with Systemic Lupus Erythematosus: A Nationwide Population-based Study in Korea
In Ah Choi¹, Ji Hyoun Kim², Sung Hae Chang³, Hyun Jung Kim⁴ and Hyeong Sik Ahn⁴, ¹Chungbuk National University, Cheongju, Republic of Korea, ²Chungbuk National University Hospital, Cheongju, Republic of Korea, ³Soonchunhyang University College of Medicine, Bongmyeong-dong, Dongnam-gu, Cheonan-si, Republic of Korea, ⁴Institute for Evidence-based Medicine, Cochrane Korea, Seoul, Republic of Korea
Background/Purpose: Systemic lupus erythematosus (SLE) is an autoimmune disease that primarily affects women of childbearing age, and epidemiologic studies have shown poor maternal and fetal…
Abstract Number: PP11 • ACR Convergence 2021
“Our Arthritis May Be Chronic but We Are Definitely Iconic” – Two Teens Created a National Podcast for Youth with Rheumatic Diseases
Trishtha Peters¹ and Natasha Trehan², ¹University of Ontario, Toronto, ON, Canada, ²University of Ottawa, Toronto, ON, Canada
Background/Purpose: Trish Peters was diagnosed with JIA at 11. She has been on Methotrexate to lessen disease activity for her knees and hands. She does…
Abstract Number: 1811 • ACR Convergence 2020
Distinctive Molecular Signatures Among Monocytes from Childhood- and Adult-onset Systemic Lupus Erythematosus: Clinical Involvement and Relevance of Sustained Anti-dsDNA Positivity
Alejandra Maria Patiño-Trives¹, Concepción Aranda-Valera², R Roldan³, Laura Pérez-Sanchez⁴, Carlos Pérez-Sánchez¹, Maria Luque-Tevar¹, Iván Arias de la Rosa¹, María-Carmen Abalos-Aguilera¹, Desirée Ruiz-Vilchez², Pedro Segui⁵, Mario Espinosa⁵, Nuria Barbarroja¹, Eduardo Collantes², María de los ángeles Aguirre-Zamorano⁵ and Chary Lopez-Pedrera¹, ¹Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Cordoba, Spain, ²Rheumatology Department, Reina Sofia University Hospital/ Maimonides Institute for Research in Biomedicine of Cordoba (IMIBIC)/ University of Cordoba, Cordoba, Spain, Córdoba, Spain, ³Hospital Universitario Reina Sofía, Cordoba, Spain, ⁴Hospital Universitario Reina Sofía, Córdoba, Spain, ⁵IMIBIC/University of Cordoba/Reina Sofia Hospital, Cordoba
Background/Purpose: By using integrative transcriptomic and protein analyses, this study aimed at identifying and characterize distinctive molecular signatures between childhood-onset (cSLE) and adult-onset Lupus (aSLE)…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].